For the analysis of a majority of biomarkers relevant for prescriptions of approved drugs in Europe, next-generation sequencing services are generally offered.

The speed of developments with regard to biomarker research and emerging techniques for pharmacogenomic testing presents a challenge to standardization and regulation in the use of companion diagnostics.